The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Medical Technology Enterprise Consortium (MTEC) -- Prototype Solutions for Peripheral Nerve Injury
The Medical Technology Enterprise Consortium (MTEC) is excited to announce a Request for Project Proposals (RPP) focused on providing innovative solutions to a critical problem in muscle denervation. The overarching goal of this program is to provide biomanufacturing or advanced development for an emerging area of medical technology and innovation that supports standard procedures toward a prototype aimed to maintain, re-establish or regenerate myoneural connections.
Technology Focus Areas
Applications must address one or more of the following focus areas in nerve regeneration or end-organ health. Specifically, MTEC seeks prototype development and/or biomanufacturing of a device, biologic, or combination prototype that supports:
- Maintenance of the post-synaptic junction in denervated muscle.
- Re-establish myoneural connections in the periphery.
- Co-regeneration of nerve and muscle.
The current effort aims to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; and translational studies to support the fluid transfer of knowledge from basic principles to clinical solutions. Purely in vitro efforts will not be considered. Proposed projects must be based on logical reasoning and sound scientific rationale that spread biomanufacturing and prototype development. Please note that awards are not to be exploratory in nature and require a foundation of preliminary data. Research involving animal or human subjects is allowed.
Deadline for White Papers: Mar. 19, 2018
The U.S. Government (USG) currently has available approximately $7 million (M) for Fiscal Year (FY) 2017.
Funds are intended to support areas of regenerative medicine manufacturing and prototyping that require development and harmonization into reproducible, consistent procedures which could stand the test of U.S. Food and Drug Administration (FDA) approval.
MTEC anticipates that 3 awards at $2.33M each (direct and indirect costs) will be made to qualified teams composed of teaming arrangements demonstrated to achieve advanced manufacturing and/or prototype development.
The Period of Performance (POP) is not to exceed 36 months.